Cardiovascular function and treatment in ß-thalassemia major: a consensus statement from the American Heart Association.

Pennell, Dudley J; Udelson, James E; Arai, Andrew E; Bozkurt, Biykem; Cohen, Alan R; Galanello, Renzo; Hoffman, Timothy M; Kiernan, Michael S; Lerakis, Stamatios; Piga, Antonio; Porter, John B; Walker, John Malcolm; Wood, John

Pennell, Dudley J; Udelson, James E; Arai, Andrew E; Bozkurt, Biykem; Cohen, Alan R; Galanello, Renzo; Hoffman, Timothy M; Kiernan, Michael S; Lerakis, Stamatios; Piga, Antonio; Porter, John B; Walker, John Malcolm; Wood, John.

Circulation ; 128(3): 281-308, 2013 Jul 16.

Article in En | MEDLINE | ID: mdl-23775258

Subject(s)

American Heart Association; Heart Failure/etiology; Heart Failure/therapy; beta-Thalassemia/complications; beta-Thalassemia/drug therapy; Consensus; Heart Failure/physiopathology; Humans; Iron Chelating Agents/therapeutic use; Iron Overload/complications; Iron Overload/drug therapy; United States

Key words

AHA Scientific Statement; CT and MRI; heart failure; other heart failure; other treatment; thalassemia

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Beta-Thalassemia / American Heart Association / Heart Failure Type of study: Clinical_trials / Guideline / Risk_factors_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Circulation Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google